Analysis of Long-term (Investment) Activity Ratios
Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Long-term Activity Ratios (Summary)
Cytokinetics Inc., long-term (investment) activity ratios
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
| Long-term activity ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | Cytokinetics Inc. net fixed asset turnover ratio deteriorated from 2020 to 2021 but then slightly improved from 2021 to 2022. |
| Net fixed asset turnover (including operating lease, right-of-use asset) | An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). | Cytokinetics Inc. net fixed asset turnover ratio (with operating lease, right-of-use asset) deteriorated from 2020 to 2021 but then slightly improved from 2021 to 2022. |
| Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | Cytokinetics Inc. total asset turnover ratio deteriorated from 2020 to 2021 but then slightly improved from 2021 to 2022. |
Net Fixed Asset Turnover
Cytokinetics Inc., net fixed asset turnover calculation, comparison to benchmarks
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Revenues | 94,588) | 70,428) | 55,828) | 26,868) | 31,501) | |
| Property and equipment, net | 80,453) | 73,271) | 13,346) | 4,530) | 3,204) | |
| Long-term Activity Ratio | ||||||
| Net fixed asset turnover1 | 1.18 | 0.96 | 4.18 | 5.93 | 9.83 | |
| Benchmarks | ||||||
| Net Fixed Asset Turnover, Competitors2 | ||||||
| AbbVie Inc. | 11.76 | 11.00 | 8.73 | 11.23 | — | |
| Amgen Inc. | 4.57 | 4.69 | 4.96 | 4.51 | — | |
| Bristol-Myers Squibb Co. | 7.38 | 7.67 | 7.22 | 4.18 | — | |
| Danaher Corp. | 7.96 | 7.77 | 6.83 | 7.78 | — | |
| Eli Lilly & Co. | 2.81 | 3.15 | 2.83 | 2.83 | — | |
| Gilead Sciences Inc. | 4.93 | 5.27 | 4.90 | 4.91 | — | |
| Johnson & Johnson | 4.79 | 4.95 | 4.40 | 4.65 | — | |
| Merck & Co. Inc. | 2.77 | 2.53 | 2.67 | 3.11 | — | |
| Moderna Inc. | 9.14 | 14.24 | 0.67 | 0.00 | — | |
| Pfizer Inc. | 6.17 | 5.46 | 3.01 | 3.71 | — | |
| Regeneron Pharmaceuticals Inc. | 3.23 | 4.62 | 2.64 | 2.72 | — | |
| Thermo Fisher Scientific Inc. | 4.84 | 4.71 | 5.45 | 5.38 | — | |
| Net Fixed Asset Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 5.02 | 5.06 | 4.27 | 4.30 | — | |
| Net Fixed Asset Turnover, Industry | ||||||
| Health Care | 10.62 | 10.44 | 9.62 | 9.73 | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Net fixed asset turnover = Revenues ÷ Property and equipment, net
= 94,588 ÷ 80,453 = 1.18
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | Cytokinetics Inc. net fixed asset turnover ratio deteriorated from 2020 to 2021 but then slightly improved from 2021 to 2022. |
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)
Cytokinetics Inc., net fixed asset turnover (including operating lease, right-of-use asset) calculation, comparison to benchmarks
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Revenues | 94,588) | 70,428) | 55,828) | 26,868) | 31,501) | |
| Property and equipment, net | 80,453) | 73,271) | 13,346) | 4,530) | 3,204) | |
| Operating lease right-of-use assets | 82,737) | 73,138) | 2,924) | —) | —) | |
| Property and equipment, net (including operating lease, right-of-use asset) | 163,190) | 146,409) | 16,270) | 4,530) | 3,204) | |
| Long-term Activity Ratio | ||||||
| Net fixed asset turnover (including operating lease, right-of-use asset)1 | 0.58 | 0.48 | 3.43 | 5.93 | 9.83 | |
| Benchmarks | ||||||
| Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Competitors2 | ||||||
| AbbVie Inc. | 10.24 | 9.57 | 7.46 | 10.06 | — | |
| Amgen Inc. | 4.13 | 4.23 | 4.58 | 4.11 | — | |
| Bristol-Myers Squibb Co. | 6.18 | 6.66 | 6.30 | 3.76 | — | |
| Danaher Corp. | 6.35 | 6.10 | 5.30 | 5.84 | — | |
| Eli Lilly & Co. | 2.63 | 2.93 | 2.63 | 2.66 | — | |
| Gilead Sciences Inc. | 4.51 | 4.77 | 4.34 | 4.28 | — | |
| Johnson & Johnson | 4.54 | 4.72 | 4.18 | 4.41 | — | |
| Merck & Co. Inc. | 2.60 | 2.33 | 2.43 | 2.90 | — | |
| Moderna Inc. | 8.62 | 12.78 | 0.52 | 0.00 | — | |
| Pfizer Inc. | 5.20 | 4.59 | 2.74 | 3.39 | — | |
| Regeneron Pharmaceuticals Inc. | 3.17 | 4.52 | 2.58 | 2.66 | — | |
| Thermo Fisher Scientific Inc. | 4.13 | 3.98 | 4.82 | 4.69 | — | |
| Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 4.52 | 4.54 | 3.88 | 3.93 | — | |
| Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Industry | ||||||
| Health Care | 8.57 | 8.28 | 7.55 | 7.63 | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset) = Revenues ÷ Property and equipment, net (including operating lease, right-of-use asset)
= 94,588 ÷ 163,190 = 0.58
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover (including operating lease, right-of-use asset) | An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). | Cytokinetics Inc. net fixed asset turnover ratio (with operating lease, right-of-use asset) deteriorated from 2020 to 2021 but then slightly improved from 2021 to 2022. |
Total Asset Turnover
Cytokinetics Inc., total asset turnover calculation, comparison to benchmarks
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Revenues | 94,588) | 70,428) | 55,828) | 26,868) | 31,501) | |
| Total assets | 1,014,775) | 841,319) | 533,803) | 289,814) | 211,178) | |
| Long-term Activity Ratio | ||||||
| Total asset turnover1 | 0.09 | 0.08 | 0.10 | 0.09 | 0.15 | |
| Benchmarks | ||||||
| Total Asset Turnover, Competitors2 | ||||||
| AbbVie Inc. | 0.42 | 0.38 | 0.30 | 0.37 | — | |
| Amgen Inc. | 0.38 | 0.40 | 0.39 | 0.37 | — | |
| Bristol-Myers Squibb Co. | 0.48 | 0.42 | 0.36 | 0.20 | — | |
| Danaher Corp. | 0.37 | 0.35 | 0.29 | 0.29 | — | |
| Eli Lilly & Co. | 0.58 | 0.58 | 0.53 | 0.57 | — | |
| Gilead Sciences Inc. | 0.43 | 0.40 | 0.36 | 0.36 | — | |
| Johnson & Johnson | 0.51 | 0.52 | 0.47 | 0.52 | — | |
| Merck & Co. Inc. | 0.54 | 0.46 | 0.52 | 0.55 | — | |
| Moderna Inc. | 0.71 | 0.72 | 0.03 | 0.00 | — | |
| Pfizer Inc. | 0.51 | 0.45 | 0.27 | 0.31 | — | |
| Regeneron Pharmaceuticals Inc. | 0.42 | 0.63 | 0.50 | 0.53 | — | |
| Thermo Fisher Scientific Inc. | 0.46 | 0.41 | 0.47 | 0.44 | — | |
| Total Asset Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 0.48 | 0.45 | 0.38 | 0.39 | — | |
| Total Asset Turnover, Industry | ||||||
| Health Care | 0.81 | 0.76 | 0.70 | 0.71 | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Total asset turnover = Revenues ÷ Total assets
= 94,588 ÷ 1,014,775 = 0.09
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | Cytokinetics Inc. total asset turnover ratio deteriorated from 2020 to 2021 but then slightly improved from 2021 to 2022. |
Equity Turnover
Cytokinetics Inc., equity turnover calculation, comparison to benchmarks
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Revenues | 94,588) | 70,428) | 55,828) | 26,868) | 31,501) | |
| Stockholders’ equity (deficit) | (107,900) | 243,863) | 113,383) | (10,937) | 25,934) | |
| Long-term Activity Ratio | ||||||
| Equity turnover1 | — | 0.29 | 0.49 | — | 1.21 | |
| Benchmarks | ||||||
| Equity Turnover, Competitors2 | ||||||
| AbbVie Inc. | 3.36 | 3.65 | 3.50 | — | — | |
| Amgen Inc. | 6.77 | 3.63 | 2.58 | 2.30 | — | |
| Bristol-Myers Squibb Co. | 1.49 | 1.29 | 1.12 | 0.51 | — | |
| Danaher Corp. | 0.63 | 0.65 | 0.56 | 0.59 | — | |
| Eli Lilly & Co. | 2.68 | 3.15 | 4.35 | 8.56 | — | |
| Gilead Sciences Inc. | 1.27 | 1.28 | 1.34 | 0.98 | — | |
| Johnson & Johnson | 1.24 | 1.27 | 1.31 | 1.38 | — | |
| Merck & Co. Inc. | 1.29 | 1.28 | 1.90 | 1.81 | — | |
| Moderna Inc. | 0.96 | 1.25 | 0.08 | 0.00 | — | |
| Pfizer Inc. | 1.05 | 1.05 | 0.66 | 0.82 | — | |
| Regeneron Pharmaceuticals Inc. | 0.54 | 0.86 | 0.77 | 0.71 | — | |
| Thermo Fisher Scientific Inc. | 1.02 | 0.96 | 0.93 | 0.86 | — | |
| Equity Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 1.25 | 1.28 | 1.23 | 1.20 | — | |
| Equity Turnover, Industry | ||||||
| Health Care | 2.17 | 2.10 | 2.07 | 2.07 | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Equity turnover = Revenues ÷ Stockholders’ equity (deficit)
= 94,588 ÷ -107,900 = —
2 Click competitor name to see calculations.